Daewoong's Nabota exceeds 600,000 customers in US

Botulinum toxin product Nabota receives 96% re-treatment rate, surpasses 10% market share in the US

Daewoong's Nabota exceeds 600,000 customers in US
Ji-Hyun Lee 1
2023-07-13 11:28:53 bluesky@hankyung.com
Bio & Pharma

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum toxin developed by the company, has surpassed 600,000 members.

The program, called Evolus Rewards, offers appointment reservations and benefits for Nabota treatments.

According to Evolus, the US partner of Daewoong Pharmaceutical, a total of 600,000 customers have joined the program since Nabota was launched in the US market in 2020. The number of treatments received through the program has exceeded 1 million cumulatively.

Nearly all members who have undergone the first treatment have registered for the second treatment, with a re-treatment rate of 96%. This is a high re-treatment rate for a loyalty program, and it suggests that Nabota is a product that customers are satisfied with.

The majority of the members are millennials or younger generations. Nabota has achieved an average annual sales growth rate of 62% in the US in the past two years, and its market share has also exceeded 10%.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#Daewoong Pharmaceutical #Nabota #Botulinum toxin product #US #sales #customers

Daewoong’s Nabota expands into Germany, Austria

Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through its overseas partner Evolus Inc., a US performance beauty company.This is the second European launch for Nabota, which is sold under the brand name Nuc

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Phamaceutical's Nabota South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) from Singapore authorities.The item that received approval this

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharma's Nabota (US brand name: Jeuveau) Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wrinkles showed a six-month long-lasting effect as a result of an interim analysis of a phase 2 clin

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Jan. 13.The item that received approval this time is Nuceiva 100 units whose application to the Australian authorities had been made by Nabota's cos

Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

Daewoong Pharmaceutical's botox product Nabota South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukraine.Saudi Arabia, one of the largest markets for botulinum toxin, more commonly known as botox, in th
(* comment hide *}